Respiratorius
Notice of allowance of patent application for VAL001
REG
The patent application allowed by the Canadian Intellectual Property Office is the first patent application on the formulation from Respiratorius, claiming a novel oral formulation of sodium valproate for pretreating cancer. The priority date of the patent application is 21 April 2016 which will be in force at least 20 years from the priority date granting market exclusivity. The application in the same patent family was allowed and issued in Japan during 2022.
This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 12-10-2023 08:29 CET.
| Datum | 2023-10-12, kl 08:29 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!